胃病的循證防治_《中國循證醫學雜志》

作者：

陳世耀 , 劉天舒 , 彭春艷 , 王吉耀

復旦大學附屬中山醫院消化科復旦大學臨床流行病/循證醫學中心,上海,200032;

關鍵詞：

慢性胃炎消化性潰瘍胃癌幽門螺桿菌循證醫學臨床證據

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

本文運用循證醫學方法對慢性胃炎、消化性潰瘍、功能性消化不良、胃食管反流等常見的胃部疾病的診治給予解釋,幫助讀者學習如何尋找臨床證據來解決臨床問題.

引用本文： 陳世耀,劉天舒,彭春艷,王吉耀. 胃病的循證防治. 中國循證醫學雜志, 2004, 04(10): 723-729. doi: 復制

1.	［1］Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. Pylori infection with gastric carcinoma: a meta analysis[J]. World J Gastroenterol, 2001; 7(5): 801-805.
2.	［2］Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis[J]. Am J Gastroenterol, 1999; 94(9): 2 373-2 379.
3.	［3］Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter pylori Study Group(EHPSG). Current concepts in the management of Helicobater pylori imfection-the Maastricht 2-2000 consensus report[J]. Aliment Pharmacol Ther, 2002; 16(2): 167-180.
4.	［4］Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy[J]. J Natl Cancer Inst, 2000; 92(23): 1 881-1 888.
5.	［5］Uemura N, Mukai T, Okamato S,Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer[J]. Cancer Epidemiol Biomarkers Prev, 1997; 6(8): 639-642.
6.	［6］Uemura N,Okamato S,Yamamoto S. Effects of Helicobacter pylori eradication on the background gastric mucosal the patients after endoscopic mucosal resection of early gastric cancer[J]. Gastroenterology, 2000; 118: A502.
7.	［7］Wong B, Lam SK, Wong W. Eradicating Helicobacter pylori infection in general population prevents gastric cancer:a 7-year prospective randomized placebo controlled study[J]. Gastroenterology, 2002; 122: A588.
8.	［8］Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2 751 patients[J]. Aliment Pharmacol Ther, 2003; 17(1): 99-109.
9.	［9］Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, Morini S. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy[J]. Aliment Pharmacol Ther, 2003; 18(6): 641-646.
10.	［10］Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials[J]. Aliment Pharmacol Ther, 2001; 15(9): 1 291-1 299.
11.	［11］Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Pharmacological interventions for non-ulcer dyspepsia[CD/M]. Issue 1. 2003. Cochrane Database Syst Rev.
12.	［12］Moayyedi P, Soo S, Deeks J. Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of H. Pylori eradication for non-ulcer dyspepsia[J]. BMJ, 2000; 321(7262): 659-664.
13.	［13］Chiba N, Grra CJD, Wilkinson JM, Hunt RH. Speed of Healing and symptom relief in grade II to IV Gastroesopgageal ruflux disease: a meta-analysis[J]. Gastroenterology, 1997; 112(6): 1 798-1 810.
14.	［14］Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice[J]. BMJ, 2001; 322(7282): 344-347.
15.	［15］Bardhan KD. Intermitten and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease[J]. Am J Gastroenterol, 2003; 98(suppl): S40-S48.
16.	［16］Asian-Pacific Consensus Conference on GORD[C]. Asia pacific digestive week 2003, 2730 September 2003, Singapore.
17.	［17］Graham DY. The changing epidemiology of GORD: geography and Helicobacter pylori[J]. Am J Gastroenterol, 2003; 98(7): 1 462-1 470.
18.	［18］Raghunath A, Hungin AP, Woff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review[J]. BMJ, 2003; 326 (7 392): 73.
19.	［19］Cremonini F, Caro SD, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, Camilleri M. Meta-analysis: The Relationship Between Helicobacter pylori Infection and Gastro-Oesophageal Reflux Disease[J]. Aliment Pharmacol Ther, 2003; 18(3): 279-289.

1. ［1］Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. Pylori infection with gastric carcinoma: a meta analysis[J]. World J Gastroenterol, 2001; 7(5): 801-805.
2. ［2］Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis[J]. Am J Gastroenterol, 1999; 94(9): 2 373-2 379.
3. ［3］Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter pylori Study Group(EHPSG). Current concepts in the management of Helicobater pylori imfection-the Maastricht 2-2000 consensus report[J]. Aliment Pharmacol Ther, 2002; 16(2): 167-180.
4. ［4］Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy[J]. J Natl Cancer Inst, 2000; 92(23): 1 881-1 888.
5. ［5］Uemura N, Mukai T, Okamato S,Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer[J]. Cancer Epidemiol Biomarkers Prev, 1997; 6(8): 639-642.
6. ［6］Uemura N,Okamato S,Yamamoto S. Effects of Helicobacter pylori eradication on the background gastric mucosal the patients after endoscopic mucosal resection of early gastric cancer[J]. Gastroenterology, 2000; 118: A502.
7. ［7］Wong B, Lam SK, Wong W. Eradicating Helicobacter pylori infection in general population prevents gastric cancer:a 7-year prospective randomized placebo controlled study[J]. Gastroenterology, 2002; 122: A588.
8. ［8］Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2 751 patients[J]. Aliment Pharmacol Ther, 2003; 17(1): 99-109.
9. ［9］Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, Morini S. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy[J]. Aliment Pharmacol Ther, 2003; 18(6): 641-646.
10. ［10］Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials[J]. Aliment Pharmacol Ther, 2001; 15(9): 1 291-1 299.
11. ［11］Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Pharmacological interventions for non-ulcer dyspepsia[CD/M]. Issue 1. 2003. Cochrane Database Syst Rev.
12. ［12］Moayyedi P, Soo S, Deeks J. Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of H. Pylori eradication for non-ulcer dyspepsia[J]. BMJ, 2000; 321(7262): 659-664.
13. ［13］Chiba N, Grra CJD, Wilkinson JM, Hunt RH. Speed of Healing and symptom relief in grade II to IV Gastroesopgageal ruflux disease: a meta-analysis[J]. Gastroenterology, 1997; 112(6): 1 798-1 810.
14. ［14］Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice[J]. BMJ, 2001; 322(7282): 344-347.
15. ［15］Bardhan KD. Intermitten and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease[J]. Am J Gastroenterol, 2003; 98(suppl): S40-S48.
16. ［16］Asian-Pacific Consensus Conference on GORD[C]. Asia pacific digestive week 2003, 2730 September 2003, Singapore.
17. ［17］Graham DY. The changing epidemiology of GORD: geography and Helicobacter pylori[J]. Am J Gastroenterol, 2003; 98(7): 1 462-1 470.
18. ［18］Raghunath A, Hungin AP, Woff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review[J]. BMJ, 2003; 326 (7 392): 73.
19. ［19］Cremonini F, Caro SD, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, Camilleri M. Meta-analysis: The Relationship Between Helicobacter pylori Infection and Gastro-Oesophageal Reflux Disease[J]. Aliment Pharmacol Ther, 2003; 18(3): 279-289.

《中國循證醫學雜志》

胃病的循證防治

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

胃病的循證防治

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料